Abstract |
Efalizumab was authorized to be put on the market in France starting July 21, 2005. Its efficacy and tolerance profile in plaque psoriasis at a dose of 1 mg kg(-1) weekly in a subcutaneous injection have been studied in phase III trials. At the current moment, more than 3,500 patients have been included in clinical trials. Flu-like symptoms ( fever, chills, headaches, nausea, vomiting, myalgia) are the most frequent adverse events. On the skin, a localized papular rash or the aggravation of the psoriasis in an edematous or even pustular form are the two most regularly observed complications. At the biological level, hyperlymphocytosis and a temporary increase in alkaline phosphatases without clinical consequences are the most frequent anomalies. We report 2 adverse events under efalizumab that to our knowledge have never been described: a case of an eczematous rash and a case of thrombocytosis.
|
Authors | D Firmin, A M Roguedas, G Lemasson, J F Abgrall, L Misery |
Journal | Dermatology (Basel, Switzerland)
(Dermatology)
Vol. 217
Issue 3
Pg. 203-6
( 2008)
ISSN: 1421-9832 [Electronic] Switzerland |
PMID | 18594143
(Publication Type: Case Reports, Journal Article)
|
Copyright | Copyright 2008 S. Karger AG, Basel. |
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- efalizumab
|
Topics |
- Adult
- Aged
- Antibodies, Monoclonal
(administration & dosage, adverse effects)
- Antibodies, Monoclonal, Humanized
- Eczema
(chemically induced)
- Female
- Humans
- Injections, Subcutaneous
- Male
- Psoriasis
(drug therapy)
- Thrombocytosis
(chemically induced)
|